← Browse by Condition
Medical Condition
ulcerative colitis
Total Trials
14
Recruiting Now
14
Trial Phases
Phase 3, Phase 1, Phase 2
NCT06042387
Recruiting
Genome Analysis Across Populations in Inflammatory Bowel Disease
Enrollment
150 pts
Location
Canada
Sponsor
Mount Sinai Hospital, Canada
NCT05784246 Phase 3
Recruiting
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis
Enrollment
60 pts
Location
United States, Belgi...
Sponsor
Eli Lilly and Company
NCT05835973
Recruiting
Evaluation of Sleep Changes in Inflammatory Bowel Diseases (IBD) Patients.
Enrollment
216 pts
Location
France
Sponsor
Hospices Civils de Lyon
NCT06550310
Recruiting
Nutrition and Clinical Outcomes in IBD
Enrollment
300 pts
Location
United Kingdom
Sponsor
Barts & The London NHS Trust
NCT05230173
Recruiting
Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
Enrollment
250 pts
Location
United States
Sponsor
University of California, San ...
NCT03816345 Phase 1
Recruiting
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
Enrollment
300 pts
Location
United States, Canad...
Sponsor
National Cancer Institute (NCI...
NCT07184996 Phase 3
Recruiting
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
Enrollment
980 pts
Location
United States, Canad...
Sponsor
Sanofi
NCT06780683
Recruiting
Efficacy and Safety of Upadacitinib in Inflammatory Bowel Disease
Enrollment
174 pts
Location
China
Sponsor
Xiang Gao
NCT01731665
Recruiting
Epidemiology of Inflammatory Bowel Disease in the Songpa-Kangdong District, Seoul, Korea.
Enrollment
2,000 pts
Location
South Korea
Sponsor
Asan Medical Center
NCT04912999
Recruiting
Inflammatory Bowel Diseases Remission Registry
Enrollment
1,000 pts
Location
Israel
Sponsor
Tel-Aviv Sourasky Medical Cent...
NCT06453317 Phase 2
Recruiting
Comparison of Ustekinumab, Infliximab and Combination Therapy in Moderately to Severely Active Ulcerative Colitis
Enrollment
172 pts
Location
Poland
Sponsor
Medical University of Lodz
NCT05479617
Recruiting
Personalised Prediction of Disease Course in Ulcerative Colitis Using Multimodal Machine Learning - Part of the Presager Project
Enrollment
400 pts
Location
Denmark
Sponsor
Copenhagen University Hospital...
NCT00001184
Recruiting
Immune Regulation in Ulcerative Colitis or Crohn s Disease
Enrollment
1,000 pts
Location
United States
Sponsor
National Institute of Allergy ...
NCT06696014
Recruiting
Mirikizumab Real World Protocol
Enrollment
100 pts
Location
United States, Canad...
Sponsor
University of North Carolina, ...